Other classes of IRAs, such as GIPR agonists (GIPRAs) like GIP[3-30]NH2, as well as dual GIPR and GLP-1R co-agonists (GIP/GLP-1RAs) like tirzepatide, have also gained attention for their effectiveness in treating diabetes and its atherosclerotic complications (17, 18). Here, GIP is linked to diabetes mellitus.